Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury

E. Letsiou, A. N. Rizzo, S. Sammani, P. Naureckas, J. R. Jacobson, Joe GN Garcia, S. M. Dudek

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Endothelial dysfunction underlies the pathophysiology of vascular disorders such as acute lung injury (ALI) syndromes. Recent work has identified the Abl family kinases (c-Abl and Arg) as important regulators of endothelial cell (EC) barrier function and suggests that their inhibition by currently available pharmaceutical agents such as imatinib may be EC protective. Here we describe novel and differential effects of imatinib in regulating lung pathophysiology in two clinically relevant experimental models of ALI. Imatinib attenuates endotoxin (LPS)-induced vascular leak and lung inflammation in mice but exacerbates these features in a mouse model of ventilator-induced lung injury (VILI). We next explored these discrepant observations in vitro through investigation of the roles for Abl kinases in cultured lung EC. Imatinib attenuates LPS-induced lung EC permeability, restores VE-cadherin junctions, and reduces inflammation by suppressing VCAM-1 expression and inflammatory cytokine (IL-8 and IL-6) secretion. Conversely, in EC exposed to pathological 18% cyclic stretch (CS) (in vitro model of VILI), imatinib decreases VE-cadherin expression, disrupts cell-cell junctions, and increases IL-8 levels. Downregulation of c-Abl expression with siRNA attenuates LPS-induced VCAM-1 expression, whereas specific reduction of Arg reduces VE-cadherin expression in 18% CS-challenged ECs to mimic the imatinib effects. In summary, imatinib exhibits pulmonary barrier-protective and antiinflammatory effects in LPS-injured mice and lung EC; however, imatinib exacerbates VILI as well as dysfunction in 18% CS-EC. These findings identify the Abl family kinases as important modulators of EC function and potential therapeutic targets in lung injury syndromes.

Original languageEnglish (US)
Pages (from-to)L259-L269
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume308
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Ventilator-Induced Lung Injury
Endothelial Cells
Lung
Phosphotransferases
Vascular Cell Adhesion Molecule-1
Acute Lung Injury
Interleukin-8
Blood Vessels
Intercellular Junctions
Imatinib Mesylate
Lung Injury
Endotoxins
Small Interfering RNA
Permeability
Interleukin-6
Pneumonia
Anti-Inflammatory Agents
Theoretical Models
Down-Regulation
Cytokines

Keywords

  • ARDS
  • Arg
  • C-Abl
  • Endothelium
  • Imatinib
  • LPS
  • Permeability
  • Stretch
  • VILI

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology
  • Physiology

Cite this

Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. / Letsiou, E.; Rizzo, A. N.; Sammani, S.; Naureckas, P.; Jacobson, J. R.; Garcia, Joe GN; Dudek, S. M.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 308, No. 3, 2015, p. L259-L269.

Research output: Contribution to journalArticle

Letsiou, E. ; Rizzo, A. N. ; Sammani, S. ; Naureckas, P. ; Jacobson, J. R. ; Garcia, Joe GN ; Dudek, S. M. / Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2015 ; Vol. 308, No. 3. pp. L259-L269.
@article{3cfd526b1b034f2ea82ad7564b54403a,
title = "Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury",
abstract = "Endothelial dysfunction underlies the pathophysiology of vascular disorders such as acute lung injury (ALI) syndromes. Recent work has identified the Abl family kinases (c-Abl and Arg) as important regulators of endothelial cell (EC) barrier function and suggests that their inhibition by currently available pharmaceutical agents such as imatinib may be EC protective. Here we describe novel and differential effects of imatinib in regulating lung pathophysiology in two clinically relevant experimental models of ALI. Imatinib attenuates endotoxin (LPS)-induced vascular leak and lung inflammation in mice but exacerbates these features in a mouse model of ventilator-induced lung injury (VILI). We next explored these discrepant observations in vitro through investigation of the roles for Abl kinases in cultured lung EC. Imatinib attenuates LPS-induced lung EC permeability, restores VE-cadherin junctions, and reduces inflammation by suppressing VCAM-1 expression and inflammatory cytokine (IL-8 and IL-6) secretion. Conversely, in EC exposed to pathological 18{\%} cyclic stretch (CS) (in vitro model of VILI), imatinib decreases VE-cadherin expression, disrupts cell-cell junctions, and increases IL-8 levels. Downregulation of c-Abl expression with siRNA attenuates LPS-induced VCAM-1 expression, whereas specific reduction of Arg reduces VE-cadherin expression in 18{\%} CS-challenged ECs to mimic the imatinib effects. In summary, imatinib exhibits pulmonary barrier-protective and antiinflammatory effects in LPS-injured mice and lung EC; however, imatinib exacerbates VILI as well as dysfunction in 18{\%} CS-EC. These findings identify the Abl family kinases as important modulators of EC function and potential therapeutic targets in lung injury syndromes.",
keywords = "ARDS, Arg, C-Abl, Endothelium, Imatinib, LPS, Permeability, Stretch, VILI",
author = "E. Letsiou and Rizzo, {A. N.} and S. Sammani and P. Naureckas and Jacobson, {J. R.} and Garcia, {Joe GN} and Dudek, {S. M.}",
year = "2015",
doi = "10.1152/ajplung.00323.2014",
language = "English (US)",
volume = "308",
pages = "L259--L269",
journal = "American Journal of Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury

AU - Letsiou, E.

AU - Rizzo, A. N.

AU - Sammani, S.

AU - Naureckas, P.

AU - Jacobson, J. R.

AU - Garcia, Joe GN

AU - Dudek, S. M.

PY - 2015

Y1 - 2015

N2 - Endothelial dysfunction underlies the pathophysiology of vascular disorders such as acute lung injury (ALI) syndromes. Recent work has identified the Abl family kinases (c-Abl and Arg) as important regulators of endothelial cell (EC) barrier function and suggests that their inhibition by currently available pharmaceutical agents such as imatinib may be EC protective. Here we describe novel and differential effects of imatinib in regulating lung pathophysiology in two clinically relevant experimental models of ALI. Imatinib attenuates endotoxin (LPS)-induced vascular leak and lung inflammation in mice but exacerbates these features in a mouse model of ventilator-induced lung injury (VILI). We next explored these discrepant observations in vitro through investigation of the roles for Abl kinases in cultured lung EC. Imatinib attenuates LPS-induced lung EC permeability, restores VE-cadherin junctions, and reduces inflammation by suppressing VCAM-1 expression and inflammatory cytokine (IL-8 and IL-6) secretion. Conversely, in EC exposed to pathological 18% cyclic stretch (CS) (in vitro model of VILI), imatinib decreases VE-cadherin expression, disrupts cell-cell junctions, and increases IL-8 levels. Downregulation of c-Abl expression with siRNA attenuates LPS-induced VCAM-1 expression, whereas specific reduction of Arg reduces VE-cadherin expression in 18% CS-challenged ECs to mimic the imatinib effects. In summary, imatinib exhibits pulmonary barrier-protective and antiinflammatory effects in LPS-injured mice and lung EC; however, imatinib exacerbates VILI as well as dysfunction in 18% CS-EC. These findings identify the Abl family kinases as important modulators of EC function and potential therapeutic targets in lung injury syndromes.

AB - Endothelial dysfunction underlies the pathophysiology of vascular disorders such as acute lung injury (ALI) syndromes. Recent work has identified the Abl family kinases (c-Abl and Arg) as important regulators of endothelial cell (EC) barrier function and suggests that their inhibition by currently available pharmaceutical agents such as imatinib may be EC protective. Here we describe novel and differential effects of imatinib in regulating lung pathophysiology in two clinically relevant experimental models of ALI. Imatinib attenuates endotoxin (LPS)-induced vascular leak and lung inflammation in mice but exacerbates these features in a mouse model of ventilator-induced lung injury (VILI). We next explored these discrepant observations in vitro through investigation of the roles for Abl kinases in cultured lung EC. Imatinib attenuates LPS-induced lung EC permeability, restores VE-cadherin junctions, and reduces inflammation by suppressing VCAM-1 expression and inflammatory cytokine (IL-8 and IL-6) secretion. Conversely, in EC exposed to pathological 18% cyclic stretch (CS) (in vitro model of VILI), imatinib decreases VE-cadherin expression, disrupts cell-cell junctions, and increases IL-8 levels. Downregulation of c-Abl expression with siRNA attenuates LPS-induced VCAM-1 expression, whereas specific reduction of Arg reduces VE-cadherin expression in 18% CS-challenged ECs to mimic the imatinib effects. In summary, imatinib exhibits pulmonary barrier-protective and antiinflammatory effects in LPS-injured mice and lung EC; however, imatinib exacerbates VILI as well as dysfunction in 18% CS-EC. These findings identify the Abl family kinases as important modulators of EC function and potential therapeutic targets in lung injury syndromes.

KW - ARDS

KW - Arg

KW - C-Abl

KW - Endothelium

KW - Imatinib

KW - LPS

KW - Permeability

KW - Stretch

KW - VILI

UR - http://www.scopus.com/inward/record.url?scp=84933047245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933047245&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00323.2014

DO - 10.1152/ajplung.00323.2014

M3 - Article

VL - 308

SP - L259-L269

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6143

IS - 3

ER -